PortfoliosLab logoPortfoliosLab logo
PBE vs. XLVI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PBE vs. XLVI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and State Street Health Care Select Sector SPDR Premium Income ETF (XLVI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PBE achieves a 0.58% return, which is significantly higher than XLVI's -0.67% return.


PBE

1D
2.04%
1M
2.68%
YTD
0.58%
6M
1.15%
1Y
30.26%
3Y*
10.44%
5Y*
3.06%
10Y*
7.55%

XLVI

1D
0.67%
1M
2.30%
YTD
-0.67%
6M
0.76%
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PBE vs. XLVI - Yearly Performance Comparison


Correlation

The correlation between PBE and XLVI is 0.71, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (All Time)
Calculated using the full available price history since Jul 31, 2025

0.71

PBE vs. XLVI - Sectors Allocation Comparison


Sectors
PBE
XLVI

Healthcare

100.0%

-

Financial Services

0.0%
100.6%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

PBE
100.0%
XLVI

-

Financial Services

PBE
0.0%
XLVI
100.6%

Basic Materials

PBE

-

XLVI

-

Communication Services

PBE

-

XLVI

-

Consumer Cyclical

PBE

-

XLVI

-

Consumer Defensive

PBE

-

XLVI

-

Energy

PBE

-

XLVI

-

Industrials

PBE

-

XLVI

-

Real Estate

PBE

-

XLVI

-

Technology

PBE

-

XLVI

-

Utilities

PBE

-

XLVI

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PBE vs. XLVI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE
PBE Risk / Return Rank: 4747
Overall Rank
PBE Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
PBE Sortino Ratio Rank: 4949
Sortino Ratio Rank
PBE Omega Ratio Rank: 4444
Omega Ratio Rank
PBE Calmar Ratio Rank: 5252
Calmar Ratio Rank
PBE Martin Ratio Rank: 4444
Martin Ratio Rank

XLVI
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBE vs. XLVI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and State Street Health Care Select Sector SPDR Premium Income ETF (XLVI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PBEXLVIDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.28

Calmar ratioReturn relative to maximum drawdown

2.59

Martin ratioReturn relative to average drawdown

7.27

PBE vs. XLVI - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


PBEXLVIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.63

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.14

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.30

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

1.33

-1.00

Drawdowns

PBE vs. XLVI - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, which is greater than XLVI's maximum drawdown of -8.14%. Use the drawdown chart below to compare losses from any high point for PBE and XLVI.


Loading charts...

Drawdown Indicators


PBEXLVIDifference

Max Drawdown

Largest peak-to-trough decline

-45.69%

-8.14%

-37.55%

Max Drawdown (1Y)

Largest decline over 1 year

-11.73%

Max Drawdown (3Y)

Largest decline over 3 years

-22.43%

Max Drawdown (5Y)

Largest decline over 5 years

-34.71%

Max Drawdown (10Y)

Largest decline over 10 years

-37.84%

Current Drawdown

Current decline from peak

-3.62%

-4.02%

+0.40%

Average Drawdown

Average peak-to-trough decline

-16.24%

-1.95%

-14.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.17%

Volatility

PBE vs. XLVI - Volatility Comparison


Loading charts...

Volatility by Period


PBEXLVIDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.63%

Volatility (6M)

Calculated over the trailing 6-month period

13.27%

Volatility (1Y)

Calculated over the trailing 1-year period

18.71%

10.94%

+7.77%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

22.54%

10.94%

+11.60%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.92%

10.94%

+13.98%

PBE vs. XLVI - Expense Ratio Comparison

PBE has a 0.59% expense ratio, which is higher than XLVI's 0.35% expense ratio.


Dividends

PBE vs. XLVI - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.05%, less than XLVI's 11.53% yield.


PositionTTM20252024202320222021202020192018201720162015
PBE
Invesco Dynamic Biotechnology & Genome ETF
1.05%1.00%0.05%0.02%0.00%0.00%0.04%0.00%0.00%0.57%0.38%1.12%
XLVI
State Street Health Care Select Sector SPDR Premium Income ETF
11.53%5.73%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


PBE and XLVI have a correlation of 0.71, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, XLVI is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

XLVI is cheaper with a 0.35% expense ratio, compared with 0.59% for PBE.

XLVI has the higher dividend yield at 11.53%, compared with 1.05% for PBE.

PBE is categorized as Health & Biotech Equities, while XLVI is Derivative Income. They also come from different issuers: Invesco and State Street. Their fees differ too: 0.59% for PBE and 0.35% for XLVI.

Portfolio Optimizer

Find the right allocation for PBE and XLVI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer